Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.

The drop in AVAX value could be attributed to the general market sentiment. It remains highly unlikely that AVAX will cross the $1,000 mark before 2031. At that market capitalization, it could be more ...